Amarin (AMRN) Stock Price, News & Analysis

Company Overview

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Key Stats

• Today's Range: $10.09 to $10.91
• 50-Day Range: $8.00 to $11.78
• 52-Week Range: $7.08 to $20.60
• Volume: 60,064 shs
• Average Volume: 74,065 shs
• Market Capitalization: $222.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Hold

Amarin Stock Analysis - MarketRank™

Amarin scored higher than 13% of companies evaluated by MarketBeat, and ranked 909th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Amarin has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Amarin has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Amarin are expected to decrease in the coming year, from ($0.15) to ($0.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Amarin is -120.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Amarin is -120.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Amarin has a P/B Ratio of 8.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.05% of the float of Amarin has been sold short.

Short Interest Ratio / Days to Cover

Amarin has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Amarin has recently decreased by 94.74%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Amarin does not currently pay a dividend.

Dividend Growth

Amarin does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.05% of the float of Amarin has been sold short.

Short Interest Ratio / Days to Cover

Amarin has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Amarin has recently decreased by 94.74%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.96

News Sentiment

Amarin has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Amarin this week, compared to 2 articles on an average week.

Search Interest

Only 4 people have searched for AMRN on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

4 people have added Amarin to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Amarin insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.96% of the stock of Amarin is held by insiders.

Percentage Held by Institutions

Only 22.25% of the stock of Amarin is held by institutions.

AMRN Stock Analysis - Frequently Asked Questions

How have AMRN shares performed this year?

Amarin's stock was trading at $9.70 at the beginning of the year. Since then, AMRN shares have increased by 11.6% and is now trading at $10.83.
View the best growth stocks for 2025 here.

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) announced its quarterly earnings results on Wednesday, March, 12th. The biopharmaceutical company reported ($2.40) EPS for the quarter, missing analysts' consensus estimates of ($1.20) by $1.20. The biopharmaceutical company had revenue of $62.31 million for the quarter, compared to the consensus estimate of $32.37 million. Amarin had a negative trailing twelve-month return on equity of 7.22% and a negative net margin of 16.33%.
Read the conference call transcript.

When did Amarin's stock split?

Amarin's stock reverse split before market open on Friday, April 11th 2025. The 1-20 reverse split was announced on Wednesday, March 12th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Does Amarin have any subsidiaries?

The following companies are subsidiaries of Amarin: Ester Neurosciences, Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharmaceuticals Ireland Limited, Amarin Pharma Inc., Amarin Switzerland GmbH, Amarin UK Limited, and Ester Neurosciences Limited.

Who are Amarin's major shareholders?

Amarin's top institutional investors include Waterfront Wealth Inc. (12.25%), OneDigital Investment Advisors LLC (3.20%) and China Universal Asset Management Co. Ltd. (0.39%). Insiders that own company stock include Aaron Berg, Steven B Ketchum, Patrick Holt and Olsen Per Wold.
View institutional ownership trends.

How do I buy shares of Amarin?

Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amarin investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

• Last Earnings: 3/12/2025
• Today: 4/30/2025
• Next Earnings (Estimated): 5/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AMRN
• CIK: 897448
• Web: www.amarincorp.com
• Phone: (531) 669-9020
• Fax: N/A
• Employees: 360
• Year Founded: 1991

Price Target and Rating

• Average Stock Price Target: $7.00
• High Stock Price Target: $7.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: -35.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($4.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-59,110,000.00
• Net Margins: -16.33%
• Pretax Margin: -12.34%
• Return on Equity: -7.22%
• Return on Assets: -4.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.23
• Quick Ratio: 2.11

Sales & Book Value

• Annual Sales: $228.61 million
• Price / Sales: 0.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.35 per share
• Price / Book: 8.03

Miscellaneous

• Outstanding Shares: 20,534,000
• Free Float: 402,623,000
• Market Cap: $222.59 million
• Optionable: Optionable
• Beta: 1.38